Clinical Review Science, medicine, and the future

Motor neurone disease

BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7191.1118 (Published 24 April 1999) Cite this as: BMJ 1999;318:1118
  1. Pamela J Shaw, Wellcome senior fellow in clinical science and professor of neurological medicine (Pamela.Shaw@ncl.ac.uk)
  1. Department of Neurology, Ward 11, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP

    Motor neurone disease is one of the most common neurodegenerative diseases of adult onset. Currently, there is no treatment that substantially slows disease progression, and average survival from the start of symptoms is only about three years. As this article discusses, however, new understanding of disease pathogenesis is suggesting the way toward more effective neuroprotective treatments aimed at slowing or arresting injury to motor neurones.

    Background

    The incidence of the disease is one to two per 100 000, and a general practice with 10 000 patients is likely to encounter a case of motor neurone disease every two to three years. The disease predominantly affects middle aged and elderly people, with a mean age of onset of 55 years, although younger people are occasionally affected. The disease is sporadic in 90% of cases, but about 10% are familial, usually with an autosomal dominant mode of inheritance.

    Fig 1

    Major factors that seem to be contributing to motor neurone injury and the cell specific features of motor neurones that may render these cells vulnerable to such insults

    The disease causes progressive injury and cell death of lower motor neurone groups in the spinal cord and brain stem and usually also of upper motor neurones in the motor cortex. Those affected typically develop a combination of upper and lower motor neurone signs, with progressive muscle weakness and wasting usually accompanied by pathologically brisk reflexes, eventually involving the limb and bulbar muscles. Clinical variants of the disease may affect purely the lower motor neurones (progressive muscular atrophy) or the upper motor neurones (primary lateral sclerosis). Death usually results from respiratory failure due to weakness of the ventilatory muscles.

    The precise causes of the neurodegenerative process remain unknown. The selectivity of the disease process for the motor system is now recognised to be relative rather than absolute. …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe